Onderneming Annexin Pharmaceuticals AB (publ) Nasdaq Stockholm
Aandelen
ANNX BTA
SE0013748894
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
- SEK | -.--% | -3,17% | -.--% |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anna Frostegård
FOU | Founder | 51 | 01-01-14 |
Chief Executive Officer | 63 | 01-01-18 | |
Director of Finance/CFO | 53 | 11-04-23 | |
Susan Suchdev
COO | Chief Operating Officer | 52 | - |
Alain Thibault
PRN | Corporate Officer/Principal | - | 18-01-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 01-01-21 |
Mårten Österlund
BRD | Director/Board Member | 67 | 01-01-21 |
Chief Executive Officer | 63 | 01-01-18 | |
Director/Board Member | 48 | 01-01-17 | |
Director/Board Member | 65 | 01-01-16 | |
Director/Board Member | 66 | 01-01-17 | |
Director/Board Member | 71 | - | |
Anthon Jahreskog
BRD | Director/Board Member | 44 | 01-01-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 526 807 199 | 256 124 467 ( 48,62 %) | 0 | 48,62 % |
Bedrijfsgegevens
Sector
Chiffre d''affaires - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,69% | 118 mld. | |
+9,84% | 106 mld. | |
-11,39% | 23,4 mld. | |
-1,69% | 22,1 mld. | |
-10,23% | 18,34 mld. | |
-41,92% | 16,59 mld. | |
-15,61% | 15,97 mld. | |
+6,56% | 14,03 mld. | |
+16,22% | 11,67 mld. |
- Beurs
- Aandelen
- Koers ANNX
- Koers ANNX BTA
- Onderneming Annexin Pharmaceuticals AB (publ)